Combivent UDV

Combivent UDV

ipratropium bromide + salbutamol


Boehringer Ingelheim


Zuellig Pharma
Concise Prescribing Info
Ipratropium Br 0.5 mg, salbutamol sulphate 2.5 mg
Reversible bronchospasm associated w/ obstructive pulmonary disease.
Dosage/Direction for Use
Adult & childn >12 yr Acute attacks 1 unit dose vial. Maintenance 1 unit dose vial tid-qid.
Hypersensitivity to atropine or its derivatives. Hypertrophic obstructive cardiomyopathy, tachyarrhythmia.
Special Precautions
Underlying severe heart disease, hypokalemia, uncontrolled DM, recent MI, severe organic heart or vascular disorders, hyperthyroidism, phaeochromocytoma, narrow-angle glaucoma, prostatic hypertrophy, bladder-neck obstruction, cystic fibrosis. Pregnancy. Avoid contact w/ eyes.
Adverse Reactions
Headache, throat irritation, cough, dry mouth, GI motility disorders (constipation, diarrhea, vomiting), nausea & dizziness.
Drug Interactions
Xanthine derivatives, glucocorticoids, steroids, diuretics, digoxin, β-blockers, MAOIs, TCA, halogenated hydrocarbon anaesth.
ATC Classification
R03AL02 - salbutamol and ipratropium bromide ; Belongs to the class of combination of adrenergics with anticholinergics, that may also include a corticosteroid. Used in the treatment of obstructive airway diseases.
Combivent UDV inhalation soln
(unit dose) 2.5 mL x 1's
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in